Express News | Q32 Bio Inc Shares Hit Record Low After Guggenheim Downgrades Stock, Last Down 21.2%
Q32 Bio Is Maintained at Outperform by BMO Capital
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday
BMO Capital Maintains Q32 Bio(QTTB.US) With Buy Rating, Cuts Target Price to $22
Guggenheim Downgrades Q32 Bio to Neutral
Q32 Bio Analyst Ratings
Q32 Bio Price Target Lowered to $22 From $64 at BMO Capital
Express News | Q32 Bio Inc : BMO Cuts Target Price to $22 From $64
Q32 Bio Price Target Lowered to $20 From $80 at Oppenheimer
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Top Midday Decliners
Sector Update: Health Care Stocks Retreat Wednesday Afternoon
Q32 Bio Shares Plummet After Downgrades, Price Target Cuts
Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?
Guggenheim Downgrades Q32 Bio(QTTB.US) to Hold Rating
Q32 Stock Craters 68% on Mixed Phase 2 Data for Bempikibart
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
Guggenheim Downgrades Q32 Bio to Neutral From Buy; Shares Plummet
Q32 Bio Tanks 68% After Update On Its Eczema And Alopecia Treatment
Q32 Bio Shares Plunge On Data From Bempikibart Trials In Atopic Dermatitis And Alopecia Areata